Jazz Pharma Lung Cancer Drug Fails Phase 3 Trial
Jazz Pharmaceuticals announced that its experimental therapy, zanidatamab, failed to reach the primary endpoint in a late-stage clinical trial for first-line treatment of advanced HER2-positive gastroesophageal adenocarcinoma. While the company intends to evaluate the full data set to determine future development paths, the setback marks a significant hurdle for its oncology pipeline. Investors reacted cautiously to the news, as the drug was seen as a key growth catalyst for the firm’s long-term portfolio.